Pharmaceutical Industry Professional Development

Upcoming Programs

Cancer Immunotherapy Webinar Series Fall 2020 - These will be LIVE 1 hour Webinars and are accredited for CPE

Cancer immunotherapy when combined with other more traditional therapies (e.g. surgery, irradiation, chemotherapeutic drugs) has led to improved survival and quality of life in affected patients. Success from immunotherapy is due to its specific mechanism of action targeting cancer cells thus reducing many adverse side effects toward normal cells and tissues. However, although cancer immunotherapy has become one of the requisites of treatment, concerns remain in limitations and lack of breadth in treating all types of cancers.  This webinar series will discuss both successful and disappointing clinical trials and therapeutic applications of cancer immunotherapy.

Who should attend?

• PhD's, MD's, PharmD's, Medical Liaisons, and Research Scientists interested in advancing their knowledge and skills in the area of immunology mechanisms and therapeutics.
• Graduate students, fellows, or trainees interested in increasing their basic and expanded knowledge of current immunotherapy concepts.
• PharmD's interested in Clinical Immunotherapy and receiving CPE Credit

REGISTRATION for those requiring CE-REGISTRATION TO OPEN LATE JULY

REGISTRATION for PhDs, Researchers and Graduate Students-REGISTRATION TO OPEN LATE JULY

Immune Mechanisms in Cancer Therapy - Wednesday, September 9, 2020  12:00 (noon) - 1:00 pm
Dr. Andrea K. Hubbard, Associate Professor; UCONN School of Pharmacy, Storrs, CT

At the conclusion of this presentation, participants will be able to:

1. Discuss basic principles of tumor cell biology and carcinogenesis
2. Discuss basic principles of tumor immune surveillance, tumor escape mechanisms and the mechanistic stages of intervention
3. Describe mechanisms underlying efficacy and modifications of monoclonal antibodies and immunotoxins in therapy
4. Identify toxicities associated with monoclonal antibody therapy
5. Describe the clinical management of monoclonal antibody therapy toxicities
   ACPE UAN:  0009-0000-20-052-L01-P

Tumor Immunotherapy: Checkpoint Inhibitors - Wednesday, September 16, 2020  12:00 (noon) - 1:00 pm
Dr. Trinh Pham, Oncology Pharmacist, Smilow Cancer Hospital, New Haven, CT

At the conclusion of this presentation, participants will be able to:

1. Describe the mechanisms underlying immune checkpoint inhibitors
2. Describe the role of immune checkpoint inhibitors in various cancer types
3. Describe the evolving role of biomarkers used to predict response to this immunotherapy
4. Identify monitoring parameters for immune-related adverse effects (irAEs) associated with immune checkpoint inhibitors
5. Identify appropriate clinical management of immune checkpoint inhibitor irAEs
   ACPE UAN:  0009-0000-20-053-L01-P

Tumor Immunotherapy: Tumor Vaccines - Wednesday, September 23, 2020   12:00 (noon) - 1:00 pm
Dr. Andrea K. Hubbard, Associate Professor; UCONN School of Pharmacy, Storrs, CT

At the conclusion of this presentation, participants will be able to:

1. Discuss basic steps in creating tumor vaccines to include personalized tumor vaccines, cancer DNA vaccines, and autologous dendritic cell vaccines
2. Describe vaccines of oncoviral therapy (oncolytic T‐VEC therapy) in select malignancies
3. Describe the clinical application and ongoing clinical trials of therapeutic cancer vaccines
4. Identify toxicities associated with tumor vaccine therapy
5. Describe the clinical management of tumor vaccine toxicities
   ACPE UAN:  0009-0000-20-054-L06-P

Tumor Immunotherapy: Chimeric Antigen Receptor (CAR) T Cell Therapy - Wednesday, September 30, 2020   12:00 (noon) - 1:00 pm
Dr. Trinh Pham, Oncology Pharmacist, Smilow Cancer Hospital,  New Haven CT

At the conclusion of this presentation, participants will be able to:

1. Describe the mechanisms underlying CAR-T cell therapy
2. Describe the role of CAR T-cell therapy in B-cell malignancies
3. Discuss the development of CAR T-cell therapy for solid tumors
4. Identify toxicities associated with CAR-T cell therapy
5. Describe the clinical management of CAR-T cell toxicities
   ACPE UAN:  0009-0000-20-055-L01-P